Cascinelli N, Vaglini M, Nava M, Santinami M, Marolda R, Rovini D, Clemente C, Bufalino R, Morabito A
J Surg Oncol. 1984 Apr;25(4):240-7. doi: 10.1002/jso.2930250404.
566 stage-II melanoma patients treated at the National Cancer Institute of Milan, Italy, were analyzed to evaluate the prognosis. Among the criteria considered, four were significantly associated with survival when considered as single factors: growth pattern, levels of invasion, the number of involved lymph nodes, and the extent of metastatic growth. As regards growth pattern, the observed 5-year survival rates were 41.9% for superficial spreading melanoma and 20.5% for nodular melanoma (P = 10(-3)). As regards levels, the 5-year survival rates were as follows: level II, 20.9%; level III, 33.1%; level IV, 43.2%; level V, 10.2% (P = 10(-3)). Patients with a partial node metastasis had 64.5% 10-year survival, while those with extension beyond the capsule had 32.6% 10-year survival (P = 10(-9). Patients with one metastatic node had 43.4% 10-year survival, and patients with three or more positive nodes had 26.0% 10-year survival (P = 10(-9)). Multifactorial analysis shows that growth pattern and extent of node metastases significantly affect survival (P = 10(-2) and P = 10(-4), respectively) while the number of involved nodes turns to borderline P-value (0.051) and the levels are no longer significant (P = 0.4).
对在意大利米兰国家癌症研究所接受治疗的566例II期黑色素瘤患者进行了分析,以评估预后。在所考虑的标准中,有四项作为单一因素时与生存率显著相关:生长模式、浸润深度、受累淋巴结数量和转移生长范围。关于生长模式,浅表扩散型黑色素瘤的观察到的5年生存率为41.9%,结节型黑色素瘤为20.5%(P = 10⁻³)。关于浸润深度,5年生存率如下:II级为20.9%;III级为33.1%;IV级为43.2%;V级为10.2%(P = 10⁻³)。有部分淋巴结转移的患者10年生存率为64.5%,而包膜外扩展的患者10年生存率为32.6%(P = 10⁻⁹)。有一个转移淋巴结的患者10年生存率为43.4%,有三个或更多阳性淋巴结的患者10年生存率为26.0%(P = 10⁻⁹)。多因素分析表明,生长模式和淋巴结转移范围显著影响生存率(分别为P = 10⁻²和P = 10⁻⁴),而受累淋巴结数量的P值接近临界值(0.051),浸润深度不再具有显著性(P = 0.4)。